stryker corp. - SYK

SYK

Close Chg Chg %
327.62 4.97 1.52%

Pre-Market

332.59

+4.97 (1.52%)

Volume: 2.22M

Last Updated:

Mar 26, 2026, 4:00 PM EDT

Company Overview: stryker corp. - SYK

SYK Key Data

Open

$326.15

Day Range

325.63 - 339.65

52 Week Range

324.93 - 404.87

Market Cap

$125.39B

Shares Outstanding

382.69M

Public Float

359.37M

Beta

0.86

Rev. Per Employee

N/A

P/E Ratio

39.01

EPS

$8.49

Yield

103.77%

Dividend

$0.88

EX-DIVIDEND DATE

Mar 31, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.28M

 

SYK Performance

1 Week
 
-0.89%
 
1 Month
 
-14.14%
 
3 Months
 
-6.08%
 
1 Year
 
-8.73%
 
5 Years
 
38.05%
 

SYK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About stryker corp. - SYK

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

SYK At a Glance

Stryker Corp.
1941 Stryker Way
Portage, Michigan 49002
Phone 1-269-385-2600 Revenue 25.12B
Industry Medical Specialties Net Income 3.25B
Sector Health Technology 2025 Sales Growth 11.157%
Fiscal Year-end 12 / 2026 Employees 56,000
View SEC Filings

SYK Valuation

P/E Current 39.013
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 41.85
Price to Sales Ratio 5.409
Price to Book Ratio 5.996
Price to Cash Flow Ratio 26.93
Enterprise Value to EBITDA 21.04
Enterprise Value to Sales 5.897
Total Debt to Enterprise Value 0.11

SYK Efficiency

Revenue/Employee 448,500.00
Income Per Employee 57,964.286
Receivables Turnover 6.218
Total Asset Turnover 0.553

SYK Liquidity

Current Ratio 1.893
Quick Ratio 1.212
Cash Ratio 0.526

SYK Profitability

Gross Margin 62.625
Operating Margin 23.276
Pretax Margin 17.973
Net Margin 12.924
Return on Assets 7.149
Return on Equity 15.079
Return on Total Capital 8.37
Return on Invested Capital 9.166

SYK Capital Structure

Total Debt to Total Equity 72.971
Total Debt to Total Capital 42.187
Total Debt to Total Assets 34.194
Long-Term Debt to Equity 67.828
Long-Term Debt to Total Capital 39.214
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Stryker Corp. - SYK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
18.45B 20.50B 22.59B 25.12B
Sales Growth
+7.84% +11.11% +10.23% +11.16%
Cost of Goods Sold (COGS) incl D&A
7.36B 7.93B 8.55B 9.39B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
998.00M 1.03B 1.05B 1.19B
Depreciation
371.00M 393.00M 427.00M 461.00M
Amortization of Intangibles
627.00M 635.00M 623.00M 732.00M
COGS Growth
+15.06% +7.65% +7.91% +9.75%
Gross Income
11.09B 12.57B 14.04B 15.73B
Gross Income Growth
+3.52% +13.40% +11.69% +12.01%
Gross Profit Margin
+60.09% +61.33% +62.15% +62.63%
2022 2023 2024 2025 5-year trend
SG&A Expense
7.31B 8.21B 8.92B 9.88B
Research & Development
1.23B 1.29B 1.41B 1.57B
Other SG&A
6.08B 6.92B 7.50B 8.32B
SGA Growth
+5.18% +12.41% +8.60% +10.81%
Other Operating Expense
- - - -
-
Unusual Expense
899.00M 412.00M 1.36B 907.00M
EBIT after Unusual Expense
2.88B 3.95B 3.76B 4.94B
Non Operating Income/Expense
139.00M 82.00M 124.00M 182.00M
Non-Operating Interest Income
94.00M 75.00M 139.00M 121.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
337.00M 356.00M 396.00M 607.00M
Interest Expense Growth
- +5.64% +11.24% +53.28%
Gross Interest Expense
337.00M 356.00M 396.00M 607.00M
Interest Capitalized
- - - -
-
Pretax Income
2.68B 3.67B 3.49B 4.51B
Pretax Income Growth
+17.62% +36.90% -4.93% +29.27%
Pretax Margin
+14.54% +17.92% +15.45% +17.97%
Income Tax
325.00M 508.00M 499.00M 1.27B
Income Tax - Current - Domestic
(12.00M) 284.00M 580.00M 563.00M
Income Tax - Current - Foreign
279.00M 430.00M 289.00M 313.00M
Income Tax - Deferred - Domestic
(209.00M) (232.00M) (538.00M) 264.00M
Income Tax - Deferred - Foreign
267.00M 26.00M 168.00M 128.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.36B 3.17B 2.99B 3.25B
Minority Interest Expense
- - - -
-
Net Income
2.36B 3.17B 2.99B 3.25B
Net Income Growth
+18.25% +34.22% -5.43% +8.45%
Net Margin Growth
+12.78% +15.44% +13.25% +12.92%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.36B 3.17B 2.99B 3.25B
Preferred Dividends
- - - -
-
Net Income Available to Common
2.36B 3.17B 2.99B 3.25B
EPS (Basic)
6.2348 8.3377 7.8556 8.4929
EPS (Basic) Growth
+17.88% +33.73% -5.78% +8.11%
Basic Shares Outstanding
378.20M 379.60M 381.00M 382.20M
EPS (Diluted)
6.1695 8.2486 7.7619 8.3984
EPS (Diluted) Growth
+18.28% +33.70% -5.90% +8.20%
Diluted Shares Outstanding
382.20M 383.70M 385.60M 386.50M
EBITDA
4.78B 5.39B 6.17B 7.04B
EBITDA Growth
+0.53% +12.75% +14.59% +14.03%
EBITDA Margin
+25.90% +26.28% +27.32% +28.03%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 428.962
Number of Ratings 31 Current Quarters Estimate 2.997
FY Report Date 03 / 2026 Current Year's Estimate 15.014
Last Quarter’s Earnings 4.47 Median PE on CY Estimate N/A
Year Ago Earnings 13.63 Next Fiscal Year Estimate 16.794
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 25 27 25
Mean Estimate 3.00 3.46 15.01 16.79
High Estimates 3.07 3.51 15.10 17.17
Low Estimate 2.92 3.27 14.96 16.60
Coefficient of Variance 1.24 1.35 0.21 0.75

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 19 19
OVERWEIGHT 7 7 6
HOLD 6 7 7
UNDERWEIGHT 0 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Stryker Corp. - SYK

Date Name Shares Transaction Value
Nov 21, 2025 Preston Wells VP, Chief Financial Officer 6,694 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $365.88 per share 2,449,200.72

Stryker Corp. in the News